Applied Evidence

Is it time to taper that opioid? (And how best to do it)

Author and Disclosure Information

 

References

Furthermore, psychiatric comorbidities,19 a personal or family history of substance use disorder,20 and a preadolescent history of sexual abuse21 are associated with a higher risk of a substance use disorder.

If OUD is identified, remain nonjudgmental and acknowledge that addiction is a chronic disease. Assumptions about a patient’s character or morality have no place in the appropriate management of OUD; remain mindful of your own implicit biases.

When is it appropriateto start an opioid taper?

The decision to taper opioids is difficult and can provoke anxiety for both prescriber and patient. Complicating matters is that there is insufficient evidence to evaluate opioid dosage-reduction interventions for patients with chronic noncancer pain.22

Safety concerns. Even in patients who are taking opioids as prescribed and for whom no red flags have been raised, the long-term safety of high-dosage opioids remains unclear. There is no “safe” dosage of opioids; however, evidence is clear that the risk of death from overdose increases with dosage. Compared with patients taking a dosage anywhere from 1 to 20 MME/d, those taking 50 to 99 MME/d have a 3.7-fold increased risk of overdose; patients taking ≥ 100 MME/d had an 8.9-fold increased risk.23 Patients for whom concomitant benzodiazepines are prescribed are also at higher risk of overdose and death. In studies of opioid overdose deaths, there was evidence of concurrent benzodiazepine use in 31% to 61% of cases.11

Inadequate analgesia. Given the well-established risk of drug tolerance, the inability to achieve or maintain pain relief or functional improvement can still occur—even when the opioid dosage is escalated reasonably. It might be prudent in that situation to taper opioids while also considering alternative modalities, including ones that were deferred previously.

Continue to: Intolerable adverse effects

Pages

Recommended Reading

Synthetic drugs pose regulatory, diagnostic challenges
Journal of Clinical Outcomes Management
Opioid prescriptions declined 33% over 5 years
Journal of Clinical Outcomes Management
Deaths from drugs, alcohol, and suicide increase among millennials
Journal of Clinical Outcomes Management
Cannabis withdrawal syndrome real but underrecognized
Journal of Clinical Outcomes Management
Medical cannabis laws appear no longer tied to drop in opioid overdose mortality
Journal of Clinical Outcomes Management
Parent education improves quick disposal of children’s unused prescription opioids
Journal of Clinical Outcomes Management
Mindfulness-based relapse prevention tied to lower anxiety, depression
Journal of Clinical Outcomes Management
Opioid exposure leads to poor perinatal and postnatal outcomes
Journal of Clinical Outcomes Management
Pharmacist stigma a barrier to rural buprenorphine access
Journal of Clinical Outcomes Management
Depression, anxiety among elderly breast cancer survivors linked to increased opioid use, death
Journal of Clinical Outcomes Management